SciSparc Advances SCI-110 with Rigorous Trial Design, But Faces Precedent Void and a Sub-Threshold Efficacy Signal

NeuroThera Labs Initiates Phase IIb Trial for Tourette Syndrome

NeuroThera Labs Inc., a subsidiary of SciSparc Ltd., has initiated a Phase IIb clinical trial site at the Yale Child Study Center in New Haven, Connecticut, for its proprietary cannabinoid-based drug candidate, SCI-110. This trial aims to evaluate SCI-110 for the treatment of Tourette Syndrome (TS) in adults, building on positive safety and efficacy results from a previous Phase IIa study that showed an average tic reduction of 21%. SCI-110 combines dronabinol with palmitoylethanolamide, designed to reduce tics and associated comorbid symptoms while minimizing side effects. The study is a randomized, double-blind, placebo-controlled, cross-over trial, with primary efficacy measured by the Yale Global Tic Severity Scale at weeks 12 and 26.

• NeuroThera Labs has significantly advanced its global development program for SCI-110 by launching a U.S. Phase IIb clinical trial site at the prestigious Yale Child Study Center. This expansion addresses a major unmet medical need for adults with Tourette Syndrome, who often experience persistent and debilitating symptoms with limited therapeutic options. The trial is also underway at Hannover Medical School in Germany and Tel Aviv Sourasky Medical Center in Israel.
• SCI-110 is a proprietary cannabinoid-based drug candidate that uniquely combines dronabinol with the endocannabinoid-like palmitoylethanolamide in a single dosage form. This innovative formulation is specifically designed to reduce tics and associated comorbid symptoms in adults with Tourette Syndrome, while simultaneously aiming to minimize potential side effects, offering a potentially safer and more effective treatment alternative.
• The ongoing Phase IIb study is a rigorous randomized, double-blind, placebo-controlled, cross-over trial evaluating the efficacy, safety, and tolerability of daily oral SCI-110 in adults aged 18-65. The primary efficacy endpoint is the change in tic severity, as measured by the gold standard Yale Global Tic Severity Scale Total Tic Score, at weeks 12 and 26 compared to baseline. Safety will be comprehensively assessed through continuous monitoring of adverse events.

Addressing the Persistent Unmet Need in Adult Tourette Syndrome

Adults with Tourette Syndrome continue to face a disproportionate burden of unmet needs, spanning inadequate access to specialized care, insufficient pharmacologic options, and a scarcity of long-term outcome data. Literature from the past three years highlights that this population reports worse mental health, physical health, and quality of life relative to the general population, while research and treatment infrastructure remain fragmented and underdeveloped.

• Access and specialist shortages: Specialized TS clinics and movement disorder specialists remain scarce, with fewer than 40% of clinicians' caseloads comprising tic disorder patients regardless of region; geographic, financial, and broadband disparities further limit access to behavioral therapy and telemedicine services.

• Pharmacotherapy gaps: Only three medications (pimozide, haloperidol, aripiprazole) hold FDA approval for TS, all dopamine receptor blockers with limited efficacy against comorbid symptoms and frequent adverse effects; this drives widespread off-label use and underscores the need for agents that address both tics and psychiatric comorbidities.

• Behavioral therapy limitations for adults: Evidence-based interventions such as CBIT and ERP have been studied predominantly in pediatric populations, with adult data limited to small trials (e.g., teleCBIT showing medium-to-large effect sizes in adults, n=10) — highlighting a need for replication across broader age ranges and treatment settings.

• Comorbidity and quality-of-life burden: TS in adults is frequently complicated by OCD, ADHD, and pathological aggression, with both tic severity and psychiatric comorbidity significantly affecting health-related quality of life, reinforcing calls for interprofessional, holistic management models.

• Research and registry gaps: Longitudinal studies in adult TS populations remain scarce, with focus groups (n=22 adults) identifying priorities including tic persistence risk factors, interactions with women's health, and relationships between TS and broader mental/physical health disorders; participants also emphasized the need for accessible, bidirectional patient registries.

• Emerging modalities still maturing: Deep brain stimulation, internet-delivered behavioral therapy, and mindfulness-based interventions (e.g., MBIT trials with 150 adults) are being explored to address treatment-refractory adult cases, but long-term efficacy, safety, and real-world effectiveness data remain limited.

Unpacking the SCI-110 Phase IIb Trial Design for Tourette Syndrome

Recent clinical investigations into Tourette Syndrome (TS) have explored a diverse range of therapeutic modalities, from pharmacological agents to non-invasive devices and behavioral interventions. Across these studies, the Yale Global Tic Severity Scale (YGTSS) consistently serves as the primary efficacy measure, providing a standardized benchmark for assessing tic severity and treatment response. The designs vary significantly, reflecting the complexity of the condition and the breadth of approaches under consideration.

Advancing Cannabinoid Therapy for Tourette Syndrome

The initiation of a Phase IIb trial for SCI-110 in Tourette Syndrome marks a pivotal moment for NeuroThera Labs and the broader field of cannabinoid-based therapeutics. Tourette Syndrome remains a challenging condition, with many patients experiencing persistent, impairing tics despite available treatments, which often come with significant side effects. This unmet need creates a clear opportunity for novel therapies.

SCI-110, combining dronabinol (Δ9-THC) with palmitoylethanolamide (PEA), represents a strategic approach to harness the known tic-reducing potential of THC while aiming to improve tolerability and address comorbidities through PEA. Previous research indicates that cannabinoids can reduce tics and premonitory urges, though the evidence base has historically been limited by small study sizes and methodological shortcomings. This Phase IIb trial, with its rigorous randomized, double-blind, placebo-controlled, cross-over design, is critical for generating the high-quality data necessary to move beyond anecdotal reports and establish a strong scientific foundation.

However, the path forward is not without its challenges. Cannabinoids are known to cause adverse events such as dizziness, somnolence, and psychiatric effects, which could impact patient adherence and the drug's overall risk-benefit profile. Furthermore, the psychoactive nature of THC can complicate trial blinding, necessitating careful design to ensure objective outcome assessment. Despite these risks, a successful trial demonstrating significant tic reduction and an acceptable safety profile could position SCI-110 as a much-needed, differentiated treatment option, potentially reshaping the therapeutic landscape for Tourette Syndrome and paving the way for broader acceptance of cannabinoid-based medicines in other neurological disorders.